Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Tianjin Lung Cancer Center, Tianjin 300060, China.
Cancer Biomark. 2017 Dec 12;21(1):169-177. doi: 10.3233/CBM-170565.
Endostar (rh-endostatin) is a new recombinant human endostatin, which could inhibit cell proliferation, angiogenesis, and tumor growth.
To explore anti-angiogenesis short-term efficacy combined with neoadjuvant chemotherapy for stage IIIA (N2) non-small cell lung cancer (NSCLC), and identify the potential predictive factors.
We pathologically examined 26 patients diagnosed with stage IIIA (N2) NSCLC who received NP chemotherapy alone or combined with Endostar, respectively.
Our results indicated that total clinical benefit rate (CBR) 87.5% and 64% (p= 0.76), respectively. The clinical benefit (CB) patients in the treatment group showed significant changes in endothelial progenitor cells (EPC), vascular endothelial growth factor (VEGF), blood flow (BF), permeability surface (PMS), and microvascular density (MVD) before and after treatment. Compared with CB patients in the control group, changes in EPC and MVD (only) before and after treatment were significant. The variation of EPC, PMS, and MVD before and after treatment in the treatment group showed positive correlation with tumor regression rate (TRR) and the variation of MVD, whereas those of EPC and PMS demonstrated positive correlations with variation of MVD before and after treatment.
Our findings suggested that PMS and EPC may be used as a predictive factor for the short-term efficacy of the combined therapy in NSCLC.
恩度（rh-endostatin）是一种新型重组人血管内皮抑制素，能抑制细胞增殖、血管生成和肿瘤生长。
探讨恩度联合新辅助化疗治疗ⅢA（N2）期非小细胞肺癌（NSCLC）的短期抗血管生成疗效及其潜在的预测因素。
对病理诊断为ⅢA（N2）期 NSCLC 且分别接受 NP 化疗联合或不联合恩度治疗的 26 例患者进行了检查。
治疗组总临床获益率（CBR）为 87.5%，对照组为 64%（p=0.76）。治疗组 CB 患者治疗前后内皮祖细胞（EPC）、血管内皮生长因子（VEGF）、血流（BF）、通透性表面（PMS）和微血管密度（MVD）均有显著变化。与对照组 CB 患者相比，治疗组 EPC 和 MVD 治疗前后的变化更为显著。治疗组 EPC、PMS 和 MVD 治疗前后的变化与肿瘤退缩率（TRR）和 MVD 治疗前后的变化呈正相关，而 EPC 和 PMS 与 MVD 治疗前后的变化呈正相关。
PMS 和 EPC 可能是预测 NSCLC 联合治疗短期疗效的一个指标。
